Nicotinamide Riboside and Brain Health: What a Major Randomized Trial Tells Us About NAD⁺ and Neuroprotection

When a Promising Biological Mechanism Meets a Large Clinical Trial

There are good scientific reasons to be interested in nicotinamide riboside. NAD⁺ participates in energy metabolism throughout the body and is required for numerous cellular processes, including redox reactions, signaling pathways, and aspects of DNA repair. Mitochondrial function depends on the efficient movement of electrons through metabolic pathways in which NAD⁺ and its reduced form, NADH, play central roles.

The possibility that NAD⁺ availability changes with aging has generated substantial research interest, particularly in tissues with high energy requirements such as the brain and skeletal muscle. Nicotinamide riboside provides one route through which cells can synthesize NAD⁺, and oral supplementation has repeatedly been shown to influence circulating NAD⁺ metabolites in human studies.

That biochemical activity makes NR a legitimate subject for clinical investigation. It does not, by itself, establish that supplementing the pathway can alter a neurodegenerative disease, restore mitochondrial function in every tissue, or improve longevity. Those outcomes require direct study in people using measurements that reflect health and function rather than cellular activity alone.

The NOPARK trial, published in JAMA on October 8, 2026, is especially informative because it moves beyond a small feasibility study or a short-term biomarker investigation. Researchers conducted a multicenter, double-blind, placebo-controlled trial to determine whether prolonged treatment with NR could improve neurological outcomes in people with early Parkinson's disease.

What the NOPARK Trial Investigated

The trial enrolled 410 participants across 11 centers in Norway. Eligible adults were at least 35 years old, had received a Parkinson's disease diagnosis within the preceding two years, and had disease characteristics consistent with early-stage Parkinson's. Participants also underwent imaging demonstrating abnormalities in the brain's dopamine transporter system and were receiving stable dopaminergic treatment before enrollment.

Researchers randomly assigned 206 participants to nicotinamide riboside and 204 to placebo. The intervention consisted of 500 mg of NR twice daily, providing a total of 1,000 mg per day, over a 52-week treatment period. Of the randomized participants, 393 were included in the primary analysis. Their mean age was approximately 65.6 years, and 34% were women.

The principal outcome was the change in the Movement Disorder Society Unified Parkinson Disease Rating Scale, combining parts I through III. This assessment captures several aspects of Parkinson's disease, including nonmotor symptoms, activities of daily living, and motor examination findings. Higher scores reflect greater disease severity.

Researchers also examined individual components of the rating scale, nonmotor symptom burden, and dopamine transporter brain imaging. These outcomes allowed the investigators to evaluate whether treatment influenced clinically meaningful disease manifestations rather than merely changing NAD⁺ metabolism.

Original research: Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease — The NOPARK Randomized Clinical Trial.

The Results: No Demonstrated Neuroprotection

At the end of 52 weeks, the combined Parkinson's rating-scale score had increased by an adjusted mean of 2.45 points among participants receiving nicotinamide riboside, while the placebo group showed a small decrease of 0.27 points. The adjusted between-group difference was 2.72 points, with a 95% confidence interval of 0.47 to 4.98 and a P value of .02, favoring placebo.

Although this difference was statistically significant, its magnitude was smaller than the trial's predefined threshold of 5.2 points for clinically important worsening. This qualification is important because statistical significance and clinical importance describe different characteristics of a result. The investigators detected a treatment-group difference unlikely to be explained by chance under the study model, but the magnitude of that difference did not reach the study's specified benchmark for a clinically meaningful deterioration on the primary scale.

Among the five prespecified key secondary outcomes, four did not show a statistically significant between-group difference. Nonmotor symptom burden, however, worsened more in the NR group, with an adjusted difference of 4.22 points compared with placebo. Measures of dopamine transporter imaging did not establish a disease-modifying benefit.

Serious adverse events occurred in 8.3% of participants assigned to NR and 14.1% assigned to placebo in the safety population. Those proportions are reassuring in some respects regarding the intervention's tolerability within this trial, but the overall safety profile does not compensate for the absence of demonstrated neurological benefit.

The investigators concluded that nicotinamide riboside did not improve clinical outcomes and that the findings do not support its use as a disease-modifying treatment for early Parkinson's disease. That conclusion is supported by the trial's primary and secondary neurological results, although the relatively modest magnitude of the observed difference should be preserved when discussing whether treatment actually worsened disease progression.

Why Parkinson's Disease Was an Important Test of NAD⁺ Biology

Parkinson's disease involves progressive dysfunction and loss of dopaminergic neurons, accompanied by disturbances in cellular protein handling, mitochondrial biology, inflammatory signaling, and other neurological processes. Mitochondrial dysfunction has long been investigated as a contributor to the disease because neurons depend on sustained energy production and have limited tolerance for disturbances in metabolic regulation.

NAD⁺ metabolism offers a plausible intervention point within this broader biology. The molecule participates in oxidation-reduction reactions essential to energy metabolism and serves as a substrate for enzymes involved in cellular signaling, stress responses, and DNA maintenance. Preclinical studies and early human investigations suggested that increasing NAD⁺ availability might influence some of the disturbances associated with Parkinson's disease.

The NOPARK trial tested whether this rationale could translate into an improvement in clinical progression over one year. Its negative findings suggest that providing additional NR at the studied dose and stage of Parkinson's disease does not produce a meaningful disease-modifying effect. Several explanations remain possible, including the complexity of neurological injury, differences between circulating NAD⁺ and tissue-specific metabolism, and biological changes that may not respond to increasing precursor availability alone.

These possibilities remain explanations to investigate rather than evidence that a different dose or treatment duration would succeed. The principal contribution of NOPARK is that it directly tested a credible hypothesis in a large, well-controlled clinical study and did not confirm the expected neurological benefit.

What Human Studies Have Established About NR and NAD⁺

One of the more consistent observations across human NR trials is that supplementation can increase circulating NAD⁺ concentrations or related metabolites. A randomized study involving older adults with mild cognitive impairment, published in GeroScience, enrolled 20 participants who received placebo or NR over ten weeks, with NR dosing increased to 1,000 mg daily. Investigators reported a 2.6-fold increase in blood NAD⁺ in the treatment group, demonstrating that the intervention affected the intended biochemical pathway.

Despite that increase, cognitive scores did not improve significantly. Exploratory analyses suggested changes in cerebral blood flow and selected epigenetic age measurements, although these results were limited by the study's small size, short duration, and statistical considerations. They did not demonstrate improved memory or slower progression toward dementia.

Another randomized pilot study in adults with amnestic mild cognitive impairment evaluated 1,000 mg of NR daily over 12 weeks. Fifty-two participants were randomized, and 42 completed the study. Blood NAD⁺ concentrations approximately doubled in the NR group, while cognitive performance and whole-brain blood flow did not significantly improve. Exploratory findings suggested increased perfusion in the left hippocampus, a region involved in memory processing, but this change was not accompanied by measurable improvement in memory performance.

These findings are scientifically useful because they indicate that NR can influence human NAD⁺ biology and may produce tissue-related physiological effects worth investigating. They also show why an increase in a metabolite, a regional blood-flow measurement, or a molecular aging marker cannot automatically be interpreted as improved neurological health.

Additional studies have investigated NR in cardiovascular and metabolic settings. A 2025 pilot randomized trial involving 54 sedentary adults aged 55 years or older examined whether NR combined with supervised walking would improve blood pressure more than walking with placebo. The combination did not outperform exercise with placebo on the primary daytime systolic blood pressure outcome, although exploratory findings suggested possible effects on certain measures of arterial stiffness or nighttime pressure in selected participants. The results support continued investigation rather than an established blood pressure treatment indication.

NAD⁺ Metabolism Is More Than a Single Supplement

NAD⁺ is central to several metabolic systems, but its biological regulation is considerably more complex than supplying one precursor. Cells synthesize, recycle, compartmentalize, and consume NAD⁺ through pathways that respond to energy demand, nutritional status, inflammation, cellular stress, and the activity of enzymes involved in signaling and repair.

NAD⁺ and NADH participate in the reactions that allow nutrients to be converted into usable cellular energy. NAD⁺ is also consumed by enzymes such as sirtuins, poly(ADP-ribose) polymerases, and CD38, each of which performs different physiological functions. Their activity varies across tissues and disease states, and changes in one component of this system may not lead to predictable improvements in the others.

This complexity is particularly relevant to aging research. NAD⁺ concentrations can change with age in certain tissues and populations, but the pattern is not identical throughout the body. Blood measurements may demonstrate that a precursor has been absorbed and metabolized without establishing that NAD⁺ availability has increased to the same degree within the brain, skeletal muscle, liver, or other organs.

The effects of supplementation also depend on whether limited NAD⁺ availability is actually contributing to the clinical problem being investigated. If disease progression is driven by multiple interacting mechanisms, increasing a single metabolic precursor may not be sufficient to influence the outcome.

HormoneSynergy® previously explored the broader biological rationale in Nicotinamide Riboside and Longevity, which discusses NAD⁺ metabolism, mitochondrial function, and cellular energy support.

What This Trial Means for Alzheimer's Disease and Cognitive Aging

Parkinson's disease and Alzheimer's disease share certain biological features, including changes in mitochondrial function, cellular stress responses, protein handling, and inflammatory activity. They are nevertheless distinct neurological diseases with different pathological characteristics, clinical presentations, and patterns of progression.

NOPARK did not study people with Alzheimer's disease, and its findings cannot establish that NR is ineffective for every aspect of cognitive aging. The smaller trials involving mild cognitive impairment provide more direct information about memory-related outcomes, but their limited sample sizes and short follow-up periods have not demonstrated clinically meaningful improvements in cognition despite reproducible changes in NAD⁺ metabolism.

An additional short-term study involving older adults with subjective cognitive decline or mild cognitive impairment reported a reduction in circulating phosphorylated tau 217, an Alzheimer's-associated biomarker, during NR supplementation compared with placebo. Cognitive performance did not significantly improve. The finding contributes to the rationale for further investigation, but it does not establish that the intervention prevents Alzheimer's disease or changes its clinical course.

As blood biomarkers become more prominent in neurodegenerative research, such distinctions will become increasingly important. Lower concentrations of an Alzheimer's-associated protein may represent a biological signal worth studying, but prevention requires evidence that people maintain memory, daily function, and independence over time.

The broader question of intervening before established cognitive impairment is discussed in HormoneSynergy®'s Alzheimer's Research Is Moving Toward Earlier Intervention.

Does the NOPARK Trial Change How NR Should Be Viewed in Longevity Medicine?

The trial substantially weakens the case for using NR as a disease-modifying treatment for Parkinson's disease at the studied dose and treatment duration. It also raises the level of evidence that should be expected before proposing NR for other neurological conditions, particularly when those proposals rely on mitochondrial biology or increased NAD⁺ concentrations rather than demonstrated functional improvement.

At the same time, the trial does not invalidate the established biochemical role of NAD⁺ or the ability of NR to act as a precursor. Those findings come from separate areas of research and remain relevant to understanding cellular physiology. Nor does a trial in people with an established neurodegenerative condition determine whether selected healthy adults may experience different metabolic responses to supplementation.

For healthy aging, however, evidence of increased NAD⁺ should be distinguished from evidence of greater energy, improved muscle performance, preserved cognition, reduced disease incidence, or longer life. Those outcomes have not been established consistently in large, long-duration randomized studies of NR.

Observations involving epigenetic clocks, regional cerebral perfusion, or other exploratory biomarkers may generate new research questions, but they should not be represented as proof of biological rejuvenation. The strongest interpretation of the current literature is that NR reliably engages an important metabolic pathway while its broader clinical benefits remain uncertain and potentially dependent on the population and outcome studied.

The HormoneSynergy® Approach

HormoneSynergy® approaches mitochondrial and cellular health as components of a broader preventive medicine strategy rather than as isolated targets for supplementation. Under the clinical leadership of Dr. Kathryn Retzler, clinical assessment considers energy metabolism alongside cardiovascular health, metabolic regulation, hormonal status, physical performance, sleep, nutritional adequacy, and the medical conditions that may contribute to fatigue or functional decline.

Interest in NAD⁺ precursors is reasonable because the pathway is essential to normal cellular function and continues to attract serious investigation in aging biology. The available human evidence supports biochemical activity, including increases in circulating NAD⁺, while the NOPARK results establish an important limitation regarding neurological disease modification. These findings can be considered together without either dismissing the underlying biology or overstating its clinical implications.

When patients report fatigue, diminished exercise recovery, cognitive concerns, or reduced physical capacity, those symptoms deserve an appropriate medical assessment. Sleep disorders, medication effects, inadequate nutrition, reduced muscle mass, cardiometabolic disease, endocrine dysfunction, and other treatable conditions may be more immediately relevant than an unmeasured change in NAD⁺ availability.

Resistance training, aerobic exercise, adequate protein and micronutrient intake, healthy glucose regulation, and management of cardiovascular risk support physiological systems that depend on normal mitochondrial function. Their clinical benefits are supported by substantially broader human outcome evidence than currently exists for NR supplementation.

Within this framework, nicotinamide riboside may be considered as an optional cellular support supplement for selected adults interested in NAD⁺ metabolism, with a clear understanding that measurable biochemical activity does not guarantee improved energy, cognition, neurological health, or longevity. Supplement decisions should reflect individual goals, medical history, concurrent medications, formulation quality, and the available evidence rather than an assumption that every biologically promising intervention is clinically necessary.

Where RetzlerRx® Synergy-NR Fits

RetzlerRx® Synergy-NR with NIAGEN® provides nicotinamide riboside as a precursor involved in NAD⁺ synthesis. Its intended role is to support normal NAD⁺ metabolism and cellular energy pathways within a broader approach to healthy aging.

The formulation is relevant to the scientific discussion because NR is an established NAD⁺ precursor with demonstrated effects on circulating NAD⁺ concentrations in human studies. Those observations support the rationale for investigating the ingredient, although they do not establish that the finished product prevents neurodegeneration, improves cognition, or extends lifespan.

The NOPARK trial evaluated NR as an investigational treatment for early Parkinson's disease and does not provide evidence supporting that indication. It also did not evaluate RetzlerRx® Synergy-NR as a commercial formulation. Patients with Parkinson's disease, cognitive impairment, or other complex neurological conditions should discuss any proposed use of NR with their treating clinicians rather than substituting supplementation for established neurological care.

For otherwise healthy adults interested in cellular energy metabolism, Synergy-NR may be considered as an optional supplement after reviewing the evidence and the broader health plan. Its most appropriate positioning is support for NAD⁺ production and normal metabolic pathways, with clinical expectations grounded in what human research has demonstrated rather than in proposed anti-aging effects.

Explore RetzlerRx® Synergy-NR — Nicotinamide Riboside and NAD⁺ Cellular Support

What the Research Tells Us About Neuroprotection

The NOPARK trial is an example of why large randomized studies are essential to evaluating promising interventions in longevity and neurological medicine. The investigators had a biologically plausible rationale supported by preclinical findings and smaller human studies, but the expected clinical benefit did not emerge after 52 weeks of treatment.

Smaller trials involving mild cognitive impairment present a related pattern. They demonstrate that NR can raise NAD⁺ levels and may influence certain exploratory measurements, yet they have not established meaningful improvements in cognitive performance. These findings leave room for further research into tissue-specific metabolism, patient selection, dosing, and other disease mechanisms without providing a clinical justification for neuroprotective claims.

For preventive longevity medicine, the appropriate interpretation is neither that NAD⁺ biology has been disproven nor that the clinical results can be set aside because the mechanism remains appealing. The biochemical pathway is well established, while its therapeutic manipulation has produced mixed and often clinically neutral human findings.

Continued investigation may eventually identify populations or conditions in which modifying NAD⁺ metabolism improves health outcomes. For now, NR is best understood as a nutrient precursor that can influence NAD⁺ metabolism, not as an established treatment for Parkinson's disease, Alzheimer's disease, or age-related neurological decline.

Related HormoneSynergy® Resources

• Nicotinamide Riboside, NAD⁺, and the Problem With Anti-Aging Hype
• Nicotinamide Riboside and Longevity
• Alzheimer's Research Is Moving Toward Earlier Intervention
• Brain Health and Longevity
• The HormoneSynergy® Longevity Medicine Model
• Optimal Aging Assessment
• RetzlerRx® Supplement Guide
• HormoneSynergy® Resource Library

Selected Research and Clinical References

1. Brakedal B, Skeie GO, Derad C, et al. Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial. JAMA. Published online October 8, 2026. Original randomized trial.
2. Orr ME, et al. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience. 2024;46:665–682. Human pilot trial.
3. A Phase-II Randomized Controlled Pilot Study of Nicotinamide Riboside Supplementation in Older Adults With Amnestic Mild Cognitive Impairment. Alzheimer's & Dementia. Cognition and cerebral blood-flow trial.
4. Cognitive and Alzheimer's Disease Biomarker Effects of Oral Nicotinamide Riboside Supplementation in Older Adults With Subjective Cognitive Decline and Mild Cognitive Impairment. Biomarker and cognitive outcomes.
5. Nicotinamide Riboside Combined With Exercise to Treat Hypertension in Middle-Aged and Older Adults: A Pilot Randomized Clinical Trial. GeroScience. 2025. Cardiovascular pilot trial.

Frequently Asked Questions

What is nicotinamide riboside?

Nicotinamide riboside is a form of vitamin B3 that serves as a precursor to NAD⁺, a coenzyme involved in cellular energy metabolism, mitochondrial function, signaling, and maintenance pathways. Human studies have demonstrated that oral NR can increase circulating NAD⁺ concentrations.

What did the 2026 NOPARK trial find?

The randomized trial enrolled 410 adults with early Parkinson's disease and evaluated 1,000 mg of NR daily for 52 weeks. NR did not improve neurological outcomes compared with placebo. The primary clinical score was statistically worse with NR, although the difference was smaller than the trial's predefined threshold for clinically important worsening.

Does nicotinamide riboside protect the brain?

NR has biologically plausible effects involving NAD⁺ metabolism, but large clinical studies have not established it as a neuroprotective treatment. The NOPARK trial did not show disease-modifying benefit in Parkinson's disease, while smaller cognitive studies have generally found biochemical changes without significant improvements in memory or cognitive performance.

Does NR increase NAD⁺ levels?

Yes. Randomized human studies have repeatedly demonstrated increases in circulating NAD⁺ concentrations or related metabolites after NR supplementation. The size of the increase varies with dose, duration, study population, and measurement methods.

Does increasing NAD⁺ improve energy or longevity?

NAD⁺ is essential to cellular energy metabolism, but increasing circulating NAD⁺ does not automatically establish improvements in perceived energy, physical function, or lifespan. Human clinical studies have not demonstrated that NR supplementation extends lifespan or consistently improves healthspan outcomes.

Can NR prevent Alzheimer's disease?

There is no established evidence that NR prevents Alzheimer's disease. Small studies in adults with mild cognitive impairment have reported increased NAD⁺ and selected exploratory biomarker changes without demonstrating meaningful improvements in cognition.

Where does RetzlerRx® Synergy-NR fit?

RetzlerRx® Synergy-NR contains nicotinamide riboside with NIAGEN® and is intended to support NAD⁺ synthesis and normal cellular energy metabolism. It may be considered as an optional nutritional supplement in an individualized wellness plan, but it is not an established treatment for Parkinson's disease, Alzheimer's disease, or neurodegeneration.

Editorial Transparency: HormoneSynergy® offers an NR-containing supplement and has a commercial interest in its sale. This article distinguishes established NAD⁺ precursor activity from unproven neurological and longevity benefits. The NOPARK trial evaluated NR as an investigational Parkinson's disease treatment and did not demonstrate clinical benefit. Product availability does not constitute evidence of effectiveness for the disease outcomes discussed.

About HormoneSynergy®: HormoneSynergy® provides evidence-based preventive longevity medicine in Portland and Lake Oswego, Oregon, under the clinical leadership of Dr. Kathryn Retzler. The clinic integrates advanced assessment, individualized treatment, and longitudinal evaluation of cardiovascular, metabolic, hormonal, cognitive, and physical health.

Medical Disclaimer: This article is educational and does not replace individualized medical advice. Nicotinamide riboside supplements are not intended to diagnose, treat, cure, or prevent disease. Patients with neurological disease, complex medical conditions, or medication concerns should consult an appropriate healthcare professional before beginning supplementation.